|
Synonyms: PF-05082566
Compound class:
Antibody
Comment: Utomilumab is a fully human IgG2 monoclonal antibody with agonist activity at the tumour necrosis factor (TNF) receptor, 4-1BB (TNFRSF9), being investigated for potential clinical anti-tumour activity [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC et al.. (2012)
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother, 61 (10): 1721-33. [PMID:22406983] |
|
2. Mittal P, Abblett R, Ryan JM, Hagymasi AT, Agyekum-Yamoah A, Svedova J, Reiner SL, St Rose MC, Hanley MP, Vella AT et al.. (2018)
An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells. J Immunol, 200 (4): 1513-1526. [PMID:29305435] |
